n restricted cash - 728,744
Net cash (used in) provided by
investing activities (834,473) 10,793,079
Cash flows from financing activities:
Proceeds from private placement of
common stock and warrants,
net of issuance costs 22,412,260 16,735,804
Proceeds from purchase of
noncontrolling interest 7,500,000 -
Proceeds from issuance of debt, net
of issue costs - 7,792,976
Payments on lines of credit (6,888,889) (2,603,524)
Proceeds from exercise of common
stock options 166,790 352,737
Net cash provided by financing
activities 23,190,161 22,277,993
Net decrease in cash and cash equivalents (12,905,023) (3,260,230)
Cash and cash equivalents, beginning
of period 14,856,738 18,116,968
Cash and cash equivalents, end of period $1,951,715 $14,856,738
'/>"/>SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1.
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million2.
MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 20083.
MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 20084.
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes5.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results6.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML7.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20078.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results9.
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences10.
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer11.
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences